- Home
- SHLS vs XNCR Comparison
SHLS vs XNCR Comparison
Compare SHLS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- XNCR
- Stock Information
- Founded
- SHLS 1996
- XNCR 1997
- Country
- SHLS United States
- XNCR United States
- Employees
- SHLS N/A
- XNCR N/A
- Industry
- SHLS Semiconductors
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- SHLS Technology
- XNCR Health Care
- Exchange
- SHLS Nasdaq
- XNCR Nasdaq
- Market Cap
- SHLS 1.1B
- XNCR 1.1B
- IPO Year
- SHLS 2021
- XNCR 2013
- Fundamental
- Price
- SHLS $10.75
- XNCR $13.40
- Analyst Decision
- SHLS Buy
- XNCR Buy
- Analyst Count
- SHLS 20
- XNCR 11
- Target Price
- SHLS $8.26
- XNCR $22.20
- AVG Volume (30 Days)
- SHLS 7.6M
- XNCR 1.4M
- Earning Date
- SHLS 11-04-2025
- XNCR 11-06-2025
- Dividend Yield
- SHLS N/A
- XNCR N/A
- EPS Growth
- SHLS N/A
- XNCR N/A
- EPS
- SHLS 0.12
- XNCR N/A
- Revenue
- SHLS $400,354,000.00
- XNCR $146,929,000.00
- Revenue This Year
- SHLS $18.14
- XNCR $23.31
- Revenue Next Year
- SHLS $14.78
- XNCR N/A
- P/E Ratio
- SHLS $86.43
- XNCR N/A
- Revenue Growth
- SHLS N/A
- XNCR N/A
- 52 Week Low
- SHLS $2.71
- XNCR $6.92
- 52 Week High
- SHLS $11.31
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- SHLS 66.40
- XNCR 56.56
- Support Level
- SHLS $9.57
- XNCR $12.17
- Resistance Level
- SHLS $10.79
- XNCR $15.69
- Average True Range (ATR)
- SHLS 0.78
- XNCR 1.15
- MACD
- SHLS 0.04
- XNCR -0.17
- Stochastic Oscillator
- SHLS 78.93
- XNCR 49.61
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.